Purpose. Peptic ulcer is a multifactorial and complex disease and affects a wide range of people worldwide. We provided a novel therapeutic approach for peptic ulcer and observed its effect. Methods. Peptic ulcer patients were enrolled from 2016 to 2017 in Chongqing and randomly assigned to two groups: a control group that used only rabeprazole and a platelet-rich plasma (PRP) group that received a combination therapy of autologous PRP (aPRP) and rabeprazole. The therapeutic effect was assessed via the ulcer size and symptom score. Results. A total of 27 patients were included (12 patients in the control group and 15 patients in the PRP group) in this study. Our results showed that all participants have healed in 30 days, and there was no significant difference in healing time between the PRP group and the control group in different independent variables. However, regression analysis revealed that the healing time was 6.99 days shorter in the PRP group than that in the control group, and patients with higher symptom scores in the initial examination need more time to heal during treatment. Endoscopic results showed that the repaired ulcer in the PRP group was more similar to the normal gastric mucosa tissue than that the control group. Conclusion. This study showed an encouraging preliminary result that aPRP has a positive result in patients with peptic ulcer and seems to be a better choice for refractory peptic ulcer treatment. Although further follow-up studies are needed to determine the duration of efficacy of aPRP, the approach will be helpful in improving the clinical treatment of peptic ulcer.
This study aims to investigate the impact of blood type, antibody titer, and pregnancy history on the incidence and severity of ABO hemolytic disease of the newborn (HDN). Data from 214 ABO HDN cases (2018–2021) were analyzed using elution tests for diagnosis and transcutaneous bilirubin for severity. The positivity rate was significantly higher in the OA group (86.73%) than in the OB group (53.47%, P < 0.01), although differences in bilirubin levels between the two groups were limited. An antibody titer of ≥ 64 was associated with a marked increase in HDN incidence; however no consistent correlation with bilirubin levels was observed. Pregnancy history showed no significant correlation. Logistic regression identified blood type and antibody titer as significant predictors of HDN incidence (odds ration [OR] = 6.09, P < 0.01; OR = 1.001, P < 0.05), whereas pregnancy history was not statistically significant (OR = 0.633, P > 0.05). The prediction model, expressed as logit(P) = ln[P/(1−P)] = 0.023 + 1.806 × blood type (1) + 0.001 × titer − 0.457 × pregnancy history (1), achieved an area under the curve (AUC) of 0.776, indicating moderate predictive accuracy. The study suggests that newborn blood type and maternal antibody titer are key factors for predicting ABO HDN incidence, though not its severity, while pregnancy history has limited relevance. This predictive model provides a moderately accurate tool for risk assessment.